Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsDennis M. Klinman, Daniela Verthelyi
Life of this patent
Estimating the term…
Abstract
A method is disclosed herein for increasing an immune response to an opportunistic infection in an immunocompromised subject. In one embodiment, the subject is infected with a lentivirus. The method includes increasing an immune response to a pathogen using D oligodeoxynucleotides including a CpG motif.
Claims12
A method of increasing an immune response to an opportunistic infection in an immunocompromised subject comprising
- selecting an immunocompromised subject infected with a secondary infection, wherein the immunocompromised subject is immunocompromised as a result of an infection with human immunodeficiency virus (HIV) or a simian immunodeficiency virus (SIV), and wherein the secondary infection is infection with a Leishmania;
- administering to the immunocompromised subject infected with the secondary infection a therapeutically effective amount of an oligodeoxynucleotide comprising the nucleic acid sequence set forth as SEQ ID NO:
- 176, an oligodeoxynucleotide comprising the nucleic acid sequence set forth as SEQ ID NO:
- 177 and an oligodeoxynucleotide comprising the nucleic acid sequence set forth as SEQ ID NO:
- 178;
- and
- assessing the immune response to the Leishmania in the subject;
- thereby increasing the response to the Leishmania in the immunocompromised subject.
A method of increasing an immune response to an opportunistic infection with a pathogen in an immunocompromised subject, comprising
- selecting an immunocompromised subject wherein the subject is immunocompromised as a result of an infection with a human immunodeficiency virus;
- and
- administering to the subject a therapeutically effective amount of an oligodeoxynucleotide comprising the nucleic acid sequence set forth as SEQ ID NO:
- 176, an oligodeoxynucleotide comprising the nucleic acid sequence set forth as SEQ ID NO:
- 177 and an oligodeoxynucleotide comprising the nucleic acid sequence set forth as SEQ ID NO:
- 178,
- wherein an antigenic epitope of a polypeptide from the pathogen is not administered to the subject,
- thereby increasing the response to the opportunistic infection, wherein the pathogen is a Leishmania.
Dependencies are inferred from the claim text.